Jiaying Yu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Jiaying Yu has a total of 34 co-authors. Here are the top co-authors by number of shared publications:
Jinhui Zhao
Department of Nutrition and Food Hygiene, Public Health College, Harbin Medical University, Harbin, PR China
3 shared publications- Liyan Liu
Department of Nutrition and Food Hygiene School of Public Health Key Laboratory of Precision Nutrition and Health, Ministry of Education Harbin Medical University Harbin China
3 shared publications - Mingjia Zhang
College of Physics and Optoelectronic Engineering, Ocean University of China, Qingdao, Shandong, 266100, China
3 shared publications - Jing Guo
School of Physics and Optoelectronics Engineering Center for Advanced Studies in Precision Instruments Hainan University Haikou Hainan China
2 shared publications Yue Lv
Hangzhou Clinical Medical College of Zhejiang Chinese Medical University, Hangzhou, China
2 shared publications- Changze Song
Department of Andrology, The Seventh Affiliated Hospital, Sun Yat-sen University, ShenZhen, China
1 shared publication
Latest Publications
- 16 September 2025
- Published by SAGE Publications in Journal of Neurotrauma
- Vol. 43 (5-6) , 508
Letter: Enhancing Outcome Assessment in TBI Studies: Integrating Functional Capacity Index with Anatomical Injury Scoring
- 16 September 2025
- Published by SAGE Publications in Journal of Neurotrauma
- Vol. 43 (5-6) , 508
Letter: Enhancing Outcome Assessment in TBI Studies: Integrating Functional Capacity Index with Anatomical Injury Scoring
- 16 June 2025
- Published by Elsevier in European Neuropsychopharmacology
- Vol. 97, 14-15
Strategies for optimizing brain-predicted age difference (Brain-PAD) Models
- 16 June 2025
- Published by Elsevier in European Neuropsychopharmacology
- Vol. 97, 14-15
Strategies for optimizing brain-predicted age difference (Brain-PAD) Models
- 6 June 2025
- Published by Elsevier in Digestive and Liver Disease
- Vol. 57 (9) , 1874
Personalized bevacizumab dosing in metastatic colorectal cancer: Statistical considerations for a phase III randomized trial
- 6 June 2025
- Published by Elsevier in Digestive and Liver Disease
- Vol. 57 (9) , 1874
Personalized bevacizumab dosing in metastatic colorectal cancer: Statistical considerations for a phase III randomized trial
- Open Access
- 20 December 2024
- Published by Springer Nature in Molecular Cancer
- Vol. 23 (1) , 1-30
Unveiling the mysteries of extrachromosomal circular DNA: from generation to clinical relevance in human cancers and health
Extrachromosomal circular DNAs (eccDNAs) are a type of circular DNAs originating from but independent of chromosomal DNAs. Nowadays, with the rapid development of sequencing and bioinformatics, the accuracy of eccDNAs detection has significantly improved. This advancement has consequently enhanced the feasibility of exploring the biological characteristics and functions of eccDNAs. This review elucidates the potential mechanisms of eccDNA generation, the existing methods for their detection and analysis, and their basic features. Furthermore, it focuses on the biological functions of eccDNAs in regulating gene expression under both physiological and pathological conditions. Additionally, the review summarizes the clinical implications of eccDNAs in human cancers and health.
- 20 December 2024
- Published by Springer Nature in Molecular Cancer
- Vol. 23 (1) , 1-30
Open AccessUnveiling the mysteries of extrachromosomal circular DNA: from generation to clinical relevance in human cancers and health
Extrachromosomal circular DNAs (eccDNAs) are a type of circular DNAs originating from but independent of chromosomal DNAs. Nowadays, with the rapid development of sequencing and bioinformatics, the accuracy of eccDNAs detection has significantly improved. This advancement has consequently enhanced the feasibility of exploring the biological characteristics and functions of eccDNAs. This review elucidates the potential mechanisms of eccDNA generation, the existing methods for their detection and analysis, and their basic features. Furthermore, it focuses on the biological functions of eccDNAs in regulating gene expression under both physiological and pathological conditions. Additionally, the review summarizes the clinical implications of eccDNAs in human cancers and health.
- 8 June 2022
- Published by Elsevier in Analytica Chimica Acta
- Vol. 1220, 340038
A multi-platform metabolomics reveals possible biomarkers for the early-stage esophageal squamous cell carcinoma
- 8 June 2022
- Published by Elsevier in Analytica Chimica Acta
- Vol. 1220, 340038
A multi-platform metabolomics reveals possible biomarkers for the early-stage esophageal squamous cell carcinoma
- 18 June 2021
- Published by Springer Nature in Cancer Gene Therapy
- Vol. 29 (6) , 770-783
MiR-181c sensitizes ovarian cancer cells to paclitaxel by targeting GRP78 through the PI3K/Akt pathway
Primary cytoreductive surgery with platinum-taxane-based chemotherapy is the standard treatment for ovarian cancer (OC) patients; however, resistance to chemotherapy is a contributing factor to OC mortality. Paclitaxel (PTX), the most widely used taxane, has become the first-line drug against OC. The molecular mechanism of PTX resistance is different from that of platinum-based agents and is still not completely elucidated. Our previous study showed that glucose-regulated protein 78 (GRP78) is involved in the resistance of OC cells to PTX. However, little is known regarding endogenous inhibitors of this gene. MicroRNAs (miRNAs) play critical roles in the regulation of gene expression; therefore, we sought to identify miRNA(s) with potential to target GRP78 under the hypothesis that miRNA(s) could serve as potential therapeutic targets. Here, we show that miR-181c, predicted to target GRP78, was downregulated in PTX-resistant OC cells and tissues. MiR-181c downregulated GRP78 expression and induced apoptosis by directly targeting its 3′-untranslated region (UTR). Overexpression of miR-181c sensitized resistant OC to PTX by inhibiting the PI3K/Akt pathway in vitro and in vivo. Taken together, our findings indicate that the delivery of miR-181c can efficiently suppress GRP78 expression and GRP78-mediated PTX resistance in OC and suggest that this strategy has therapeutic potential.
- 18 June 2021
- Published by Springer Nature in Cancer Gene Therapy
- Vol. 29 (6) , 770-783
MiR-181c sensitizes ovarian cancer cells to paclitaxel by targeting GRP78 through the PI3K/Akt pathway
Primary cytoreductive surgery with platinum-taxane-based chemotherapy is the standard treatment for ovarian cancer (OC) patients; however, resistance to chemotherapy is a contributing factor to OC mortality. Paclitaxel (PTX), the most widely used taxane, has become the first-line drug against OC. The molecular mechanism of PTX resistance is different from that of platinum-based agents and is still not completely elucidated. Our previous study showed that glucose-regulated protein 78 (GRP78) is involved in the resistance of OC cells to PTX. However, little is known regarding endogenous inhibitors of this gene. MicroRNAs (miRNAs) play critical roles in the regulation of gene expression; therefore, we sought to identify miRNA(s) with potential to target GRP78 under the hypothesis that miRNA(s) could serve as potential therapeutic targets. Here, we show that miR-181c, predicted to target GRP78, was downregulated in PTX-resistant OC cells and tissues. MiR-181c downregulated GRP78 expression and induced apoptosis by directly targeting its 3′-untranslated region (UTR). Overexpression of miR-181c sensitized resistant OC to PTX by inhibiting the PI3K/Akt pathway in vitro and in vivo. Taken together, our findings indicate that the delivery of miR-181c can efficiently suppress GRP78 expression and GRP78-mediated PTX resistance in OC and suggest that this strategy has therapeutic potential.
- 4 January 2021
- Published by Wiley in Rapid Communications in Mass Spectrometry
- Vol. 35 (7) , e9042
A novel ISM‐SAM strategy, based on gas chromatography/mass spectrometry analysis, to compensate for matrix effects in the determination of pyruvic acid
Rationale: The matrix effect is tricky in gas chromatography/mass spectrometry (GC/MS) analyses. Although several methods have been proposed to solve this problem, the results were unsatisfactory. Even fewer studies have assessed the performance of corrective methods. Hence, our study focused on assessing several common corrective methods, and then proposed a new strategy to correct for the matrix effect in GC/MS analyses. Methods: In GC/MS analyses, the internal standard method (ISM) was employed to overcome the matrix effect during the detection of pyruvic acid (PA) in serum samples from a healthy adult female. The accuracy of the ISM was evaluated by comparing it with the standard addition method (SAM). To employ the ISM‐SAM strategy, correction factors (CFs) were established by combining the ISM and the SAM based on different groups. The CFs were used to normalize data onto the results of subsequent analyses. Results: When using the ISM to detect levels of PA, a serious bias is observed, thereby affecting the conclusions reached. In contrast, more reliable data can be obtained after normalizing results by undertaking the ISM‐SAM strategy. The feasibility of this strategy was verified by comparing it with the results of the SAM alone. The ISM‐SAM strategy was successfully applied to quantify the PA levels in healthy people and nephrotic syndrome patients. Conclusions: Our results indicated that a false outcome was presented when only the ISM was used to adjust the data, and important information would be missed if the correction strategy was not carried out. Therefore, ISM‐SAM, as an available correction method, should be adapted to improve the reliability of research results.
- 4 January 2021
- Published by Wiley in Rapid Communications in Mass Spectrometry
- Vol. 35 (7) , e9042
A novel ISM‐SAM strategy, based on gas chromatography/mass spectrometry analysis, to compensate for matrix effects in the determination of pyruvic acid
Rationale: The matrix effect is tricky in gas chromatography/mass spectrometry (GC/MS) analyses. Although several methods have been proposed to solve this problem, the results were unsatisfactory. Even fewer studies have assessed the performance of corrective methods. Hence, our study focused on assessing several common corrective methods, and then proposed a new strategy to correct for the matrix effect in GC/MS analyses. Methods: In GC/MS analyses, the internal standard method (ISM) was employed to overcome the matrix effect during the detection of pyruvic acid (PA) in serum samples from a healthy adult female. The accuracy of the ISM was evaluated by comparing it with the standard addition method (SAM). To employ the ISM‐SAM strategy, correction factors (CFs) were established by combining the ISM and the SAM based on different groups. The CFs were used to normalize data onto the results of subsequent analyses. Results: When using the ISM to detect levels of PA, a serious bias is observed, thereby affecting the conclusions reached. In contrast, more reliable data can be obtained after normalizing results by undertaking the ISM‐SAM strategy. The feasibility of this strategy was verified by comparing it with the results of the SAM alone. The ISM‐SAM strategy was successfully applied to quantify the PA levels in healthy people and nephrotic syndrome patients. Conclusions: Our results indicated that a false outcome was presented when only the ISM was used to adjust the data, and important information would be missed if the correction strategy was not carried out. Therefore, ISM‐SAM, as an available correction method, should be adapted to improve the reliability of research results.
- 3 December 2019
- Published by Taylor & Francis in Expert Review of Gastroenterology & Hepatology
- Vol. 14 (1) , 9-25
Metabolomics studies in gastrointestinal cancer: a systematic review
Introduction: This systemic review provides an overview of metabolic perturbations and possible mechanisms in gastrointestinal cancer. The authors discuss emerging challenges of technical and clinical applications.Areas covered: In this systemic review, the authors summarized the currently available results of metabolomic biomarkers linked to GI cancer, and discussed the altered metabolism pathways including carbohydrate metabolism, amino acid metabolism, lipids, and nucleotide metabolism and other metabolisms. Furthermore, future efforts need to adhere to normalize analysis procedures, validate with the larger cohort and utilize multiple-omics technologies. The search was conducted in PubMed with the following search terms (biomarker, gastrointestinal cancer, colorectal cancer, and esophageal cancer) from 2013 to 2019.Expert opinion: This systemic review summarized the currently available results of metabolomic biomarkers linked to gastrointestinal cancer, and discussed the altered metabolism pathways. The authors believe that metabolomics will benefit deeper understandings of the pathogenic mechanism, discovery of biomarkers and aid the search for drug targets as we move toward the era of personalized medicine. Personalized medication for tumors can improve the curative effect, avoid side effects and medical resource waste. As a promisingtool, metabolomics that targets the entire cancer-specific metabolite network should be applied more widely in cancer research.
- 3 December 2019
- Published by Taylor & Francis in Expert Review of Gastroenterology & Hepatology
- Vol. 14 (1) , 9-25
Metabolomics studies in gastrointestinal cancer: a systematic review
Introduction: This systemic review provides an overview of metabolic perturbations and possible mechanisms in gastrointestinal cancer. The authors discuss emerging challenges of technical and clinical applications.Areas covered: In this systemic review, the authors summarized the currently available results of metabolomic biomarkers linked to GI cancer, and discussed the altered metabolism pathways including carbohydrate metabolism, amino acid metabolism, lipids, and nucleotide metabolism and other metabolisms. Furthermore, future efforts need to adhere to normalize analysis procedures, validate with the larger cohort and utilize multiple-omics technologies. The search was conducted in PubMed with the following search terms (biomarker, gastrointestinal cancer, colorectal cancer, and esophageal cancer) from 2013 to 2019.Expert opinion: This systemic review summarized the currently available results of metabolomic biomarkers linked to gastrointestinal cancer, and discussed the altered metabolism pathways. The authors believe that metabolomics will benefit deeper understandings of the pathogenic mechanism, discovery of biomarkers and aid the search for drug targets as we move toward the era of personalized medicine. Personalized medication for tumors can improve the curative effect, avoid side effects and medical resource waste. As a promisingtool, metabolomics that targets the entire cancer-specific metabolite network should be applied more widely in cancer research.